THOMAS JAMES DOYLE - 02 Jan 2024 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
SVP, Finance & Accounting
Signature
Teresa Bair, Attorney-in-fact for Thomas Doyle
Issuer symbol
KURA
Transactions as of
02 Jan 2024
Net transactions value
$0
Form type
4
Filing time
04 Jan 2024, 16:08:02 UTC
Previous filing
21 Feb 2023
Next filing
31 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +21,250 +73% $0.000000 50,411 02 Jan 2024 Direct F1, F2
holding KURA Common Stock 500 02 Jan 2024 spouse's 401(k)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +42,500 $0.000000 42,500 02 Jan 2024 Common Stock 42,500 $15.36 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/25, 1/26/26, 1/26/27 and 1/26/28.
F2 Includes 1,489 shares acquired on May 17, 2023 and 206 shares acquired on November 17, 2023 pursuant to the Issuer's Employee Stock Purchase Plan.
F3 This option vests in 48 equal monthly installments commencing on the grant date.